Hemoslemix公司的股票跌跌22.7%,引起了人们的担忧,尽管有人购买了新的内幕购买。 Hemostemix Inc.'s stock plummeted 22.7%, raising concerns despite a new insider purchase.

加拿大一家生物技术公司Hemostemix Inc.,星期一股票下跌22.7%,关闭时为0.09科多巴元。 Hemostemix Inc., a Canadian biotech firm, saw its stock plunge 22.7% on Monday, closing at C$0.09. 该公司开发血源干细胞疗法,其交易量增加了353%,交易额为2 202 367股。 The company, which develops blood-derived stem cell therapies, experienced a 353% increase in trading volume with 2,202,367 shares traded. Hemostemix的主要产品ACP-01正在第二阶段进行治疗血管疾病的试验。 Hemostemix's lead product, ACP-01, is in Phase II trials for treating vascular diseases. 尽管最近有内幕购买,投资者仍对股票的未来感到关切。 Despite a recent insider purchase, investors are concerned about the stock's future.